Skip Navigation



Annals of Oncology Advance Access published online on March 17, 2006
Annals of Oncology, doi:10.1093/annonc/mdj105
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/6/897    most recent
mdj105v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tanvetyanon, T.
Right arrow Articles by Stiff, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanvetyanon, T.
Right arrow Articles by Stiff, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received September 20, 2005
Revised November 8, 2005
Accepted November 9, 2005

review

Management of the adverse effects associated with intravenous bisphosphonates

T. Tanvetyanon 1 * and P. J. Stiff 2

1 H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL, USA
2 Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA

* To whom correspondence should be addressed.
T. Tanvetyanon, E-mail: tanvett{at}moffitt.usf.edu


  Abstract

Intravenous bisphosphonates are widely used to treat hypercalcemia and to reduce skeletal-related morbidity among cancer patients. However, serious complications, generally occurring in less than 2% of patients participated in phase III clinical trials, including acute systemic inflammatory reaction, ocular inflammation, renal failure, nephrotic syndrome, electrolyte imbalance, and osteonecrosis of the maxilla and mandible have all been increasingly reported. Yet, strategies to deal with these complications are becoming clear. Acute systemic inflammatory reaction is often self-limited and becomes less intense during subsequent treatments. For patients who develop ocular symptoms, prompt ophthalmologic evaluation is crucial to determine the safety of a subsequent bisphosphonate therapy. Patients who receive long-term pamidronate should be evaluated at intervals for early sign of nephritic syndrome as timely cessation of the agent may result in a full recovery. To reduce the risk of severe electrolyte abnormalities, particularly hypocalcemia, correcting any pre-treatment electrolyte abnormality and supplementing vitamin D and calcium may be helpful. Finally, to reduce the risk of osteonecrosis of the maxilla and mandible, obtaining a full dental evaluation before treatment and avoidance of invasive dental procedures is suggested. The three commonly used intravenous bisphosphonates (pamidronate, zoledronic acid, and ibandronate), are generally safe; ibandronate has to date been the least reported to be associated with renal side effects. As clinical indications of intravenous bisphosphonates continue to expand, prescribing clinicians should be familiar with these possible adverse effects and discuss them with patients before commencing or continuing on therapy.

Keywords: bisphosphonate; pamidronate; zoledronic acid; clodronate; ibandronate; side effect.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc., August 1, 2009; 20(8): 1303 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
K. Olson and C. Van Poznak
Significance and impact of bisphosphonate-induced acute phase responses
Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 223 - 229.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Bodmer, P. Amico, M. J. Mihatsch, M. Haschke, O. Kummer, S. Krahenbuhl, and M. Mayr
Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2366 - 2370.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. G. Shenker and A. S. M. Jawad
Bisphosphonates and osteonecrosis of the jaw
Rheumatology, July 1, 2007; 46(7): 1049 - 1051.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
B. G. M. Durie and IMWG
Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement
Mayo Clin. Proc., April 1, 2007; 82(4): 516 - 517.
[Full Text] [PDF]

Home page
 Ann OncolHome page
D Aguiar Bujanda, U Bohn Sarmiento, M. Cabrera Suarez, and J Aguiar Morales
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis
Ann. Onc., March 1, 2007; 18(3): 556 - 560.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli
The Use of Bisphosphonates in Elderly Cancer Patients
Oncologist, January 1, 2007; 12(1): 62 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
J. M. Hollander and J. I. Mechanick
Nutrition Support and the Chronic Critical Illness Syndrome
Nutr Clin Pract, December 1, 2006; 21(6): 587 - 604.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A Berruti, M Tucci, D Generali, A Mosca, M Ardine, F Vana, and L Dogliotti
Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation
Ann. Onc., December 1, 2006; 17(12): 1854 - 1855.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al.
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.